(Q50656512)

English

Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.

scientific article published in November 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

1 reference

based on heuristic

inferred from title

author name string

G Torrance

1

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

V Walker

2

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

R Grossman

3

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

J Mukherjee

4

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

D Vaughan

5

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

J La Forge

6

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

N Lampron

7

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

publication date

1 November 1999

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

16

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

5 Pt 1

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

499-520

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

https://scigraph.springernature.com/pub.10.2165/00019053-199916050-00007

0 references

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multi-attribute preference functions. Health Utilities Index

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The French version of the Nottingham Health Profile. A comparison of items weights with those of the source version

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring health status: a new tool for clinicians and epidemiologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug prices and third party payment: do they influence medication selection?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multi-attribute health status classification systems. Health Utilities Index

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resource costing for multinational neurologic clinical trials: methods and results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. A double-blind crossover study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exorcising protocol-induced spirits: making the clinical trial relevant for economics

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Issues in the cross-national assessment of health technology

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The St George's Respiratory Questionnaire

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/10662396

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00019053-199916050-00007

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/10662396

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50656512&oldid=1542554665"